• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Emergency

No mortality benefit found for hydroxychloroquine or tocilizumab for the treatment of COVID-19

byKathleen LauandAlex Chan
August 20, 2020
in Emergency, Infectious Disease, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Vaccination boosted immunity acquired from previous SARS-CoV-2 infection

Single-dose Ad26.COV2.S vaccine provides moderate protection against Covid-19 related outcomes

BNT162b2 safe and efficacious in children 5 to 11 years of age

1. Hydroxychloroquine use in hospitalized and tocilizumab use in ICU lab-positive COVID-19 patients were not been associated with decreased death.

Evidence Rating Level: 2 (Good)

There is ongoing research into evaluating potential treatment options for COVID-19. Despite conflicting evidence, hydroxychloroquine (with or without azithromycin) remains a popular option, while  preliminary results from CORIMUNO-TOCI trial show potential for tocilizumab, an IL-6 inhibitor, as an emerging treatment option. Hydroxychloroquine’s mechanism of action is thought to involve preventing viral entry by affecting angiotensin converting enzyme 2 and raising the pH of endosomes (via studies done on the original SARS-CoV virus) and by decreasing pro inflammatory cytokines and inhibiting signalling pathways by accumulating in lymphocytes and macrophages, while tocilizumab mediated IL-6 blockade is thought to prevent its effect of the interleukin on cytokine storms. Recent observational cohort studies of 1376 and 1438 patients show no association between hydroxychloroquine and intubation or death (HR 1.04, HR 1.35), even with azithromycin (HR 1.08). In this retrospective, observational, multicenter cohort study, 2512 hospitalized SARS-CoV 2 PCR-positive patients had received either hydroxychloroquine, hydroxychloroquine and azithromycin, azithromycin or neither therapy and the association with associated death was examined. Patients hospitalized between March 1 2020 to April 22, 2020 were chosen and followed-up with until May 5, 2020. Propensity-score adjusted analysis did not show decrease mortality with hydroxychloroquine (aHR 1.02, 95% 0.82-1.27), hydroxychloroquine and azithromycin (aHR 0.98, 95% CI 0.75-1.28), azithromycin (aHR 0.89, 95% CI 0.72-1.10). An additional component of this study is the evaluation of 547 SARS-CoV2 PCR-positive patients in the ICU and the association of tocilizumab exposure during their ICU stay (n=134) with associated mortality. Propensity-score adjusted analysis did not show a significant difference in mortality compared to no exposure however a trend was noted (aHR 0.76, 95% CI 0.57-1.00). Study findings are in keeping with recent literature that have found questionable benefits for the use of hydroxychloroquine for treatment of COVID-19. Likewise, no mortality benefit was found for the use of tocilizumab, though further larger scaled randomized studies may provide further insight into the trends observed in the present trial.

Click to read the study in PlosONE

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: hydroxychloroquineintensive careSARS-CoV-2
Previous Post

#VisualAbstract: Association between antidepressants during early pregnancy and risk of birth defects

Next Post

#VisualAbstract: 3-day vs. 5-day amoxicillin treatment for chest-indrawing pneumonia in children from Malawi

RelatedReports

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Vaccination boosted immunity acquired from previous SARS-CoV-2 infection

May 13, 2022
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

Single-dose Ad26.COV2.S vaccine provides moderate protection against Covid-19 related outcomes

May 13, 2022
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

BNT162b2 safe and efficacious in children 5 to 11 years of age

May 13, 2022
Masks for personal protection for SARS-CoV-2 infection
Chronic Disease

Adding mask recommendation did not significantly reduce the SARS-CoV-2 infection rate

May 13, 2022
Next Post
#VisualAbstract: Household transmissibility of SARS-CoV-2

#VisualAbstract: 3-day vs. 5-day amoxicillin treatment for chest-indrawing pneumonia in children from Malawi

Stochastic resonance stimulation may decrease apnea of prematurity

Iodine deficiency associated with adverse fetal and gestational outcomes

Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail

Use of drug-coated balloons for treatment of stenotic lesions in arteriovenous fistulas

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.